March 13, 2023
STAT: The second age of psychedelic therapies for mental health
February 22, 2023
Leafly: Can psychedelic mushrooms trigger psychosis?
February 16, 2023
Bioworld: Trip wire: News due soon from varied developers in psychedelic space could trigger still more interest
February 14, 2023
Green Market: Reunion Neuroscience Reports Earnings, Update on Postpartum Drug Study
February 14, 2023
Benzinga: Reunion Neuroscience Touts ‘Transformative’ Quarter, Reaffirms Postpartum Depression Treatment
January 24, 2023
Behavioral Health Business: Why 2023 Could be a Pivotal Year for Psychedelic-Assisted Treatment
January 18, 2023
MarketWatch: Reunion Neuroscience Taps Robert Alexander as Chief Medical Officer
January 18, 2023
Wall Street Journal: Reunion Neuroscience Taps Robert Alexander as Chief Medical Officer
January 18, 2023
Becker’s Physician Leadership / Becker’s Hospital Review: Former Pfizer, Merck executive joins Reunion Neuroscience
January 18, 2023
Seeking Alpha: Reunion Neuroscience appoints Robert Alexander as Chief Medical Officer
January 16, 2023
HIT Consultant: 22 Executive Digital Health Predictions to Watch in 2023
January 16, 2023
Psychedelic Invest: Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th
January 13, 2023
Psychedelic Invest: Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th
January 10, 2023
Psychedelic Health: Psychedelic compound shown to be safe in postpartum trial
January 9, 2023
Benzinga: Could This New Psychedelic Substance Help Treat Postpartum Depression? Researchers Aim To Find Out
January 9, 2023
Green Market Report: Postpartum Depression Psychedelic Treatment Studied In Reunion’s Phase 1 Trial
January 6, 2023
Green Market Report: An Objective Look at the Psychedelics Industry for 2023
January 3, 2023
Green Market Report: 2023 Will Be The Breakout Year for Psychedelics
December 21, 2022
Green Market Report / Psychedealia: How 5 Psychedelics Companies Fared in 2022
December 18, 2022
Wall Street Journal: Drug Companies Join Medical Psychedelic Movement—But Without the High
December 1, 2022
Life Science Leader: Will The Finance And Funding Pendulum Swing Back To Black In 2023?
November 23, 2022
Psychiatric Times: Promising New Treatments For Postpartum Depression
October 28, 2022
Endpoints News: Peer Review
October 26, 2022
Fortune: CFO Daily Newsletter
October 24, 2022
BioWorld: Appointments And Advancements
October 24, 2022
Psychedelic Invest: Reunion Neuroscience Appoints Chief Financial Officer And Vice President, Medical Affairs
October 13, 2022
The Fly: Reunion CEO, CSO Talk Psychedelic Drug Development, Challenges, Opportunities, And More
September 30, 2022
Endpoints News: Peer Review
September 29, 2022
Drug Discovery & Development: An Inside Look At Reunion Neuroscience’s Psychedelic Strategy For Treating Depression
September 29, 2022
Psychedelic Invest: Reunion Neuroscience Inc. Appoints Greg Mayes As President And Chief Executive Officer
September 28, 2022
Seeking Alpha: Reunion Neuroscience Appoints Greg Mayes As President And CEO
September 28, 2022
Drug Discovery & Development: Reunion Neuroscience Names New CEO To Guide Development Of Psychedelic Depression Therapy
September 28, 2022
MarketWatch: Reunion Neuroscience Names Mayes As President, CEO